The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Studenikina A.A.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

Mangazeeva E.D.

Novosibirsk State Medical University

Bogachuk A.P.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry

Lipkin V.M.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry

Autenshlyus A.I.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer

Authors:

Studenikina A.A., Mangazeeva E.D., Bogachuk A.P., Lipkin V.M., Autenshlyus A.I.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2025;87(2): 5‑10

DOI: 10.17116/patol2025870215

Read: 659 times

Download PDF (RU)
Contact the author
Table of contents

THE EFFECT OF ACETYLAMIDE SYNTHETIC PEPTIDE HLDF-6 ON CELL DIFFERENTIATION IN BREAST CANCER
THE EFFECT OF ACETYLAMIDE SYNTHETIC PEPTIDE HLDF-6 ON CELL DIFFERENTIATION IN BREAST CANCER

To cite this article:

Studenikina AA, Mangazeeva ED, Bogachuk AP, Lipkin VM, Autenshlyus AI. The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;87(2):5‑10. (In Russ.)
https://doi.org/10.17116/patol2025870215

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
NDRG1 protein expression in breast cancer samples, rela­tionship with lymph nodes meta­stasis. Russian Journal of Archive of Pathology. 2024;(6):36-42
Capsular contracture after reco­nstructive plastic surgery for breast cancer. P.A. Herzen Journal of Onco­logy. 2024;(6):78-83
Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study. Piro­gov Russian Journal of Surgery. 2024;(12):38-43
Asse­ssment of risk factors for breast cancer deve­lopment in women living in the Sara­tov region. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):100-106
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Nottingham Prognostic Index rela­tion to cyto­kine-producing tumor mole­cular subtypes in breast cancer. Russian Journal of Preventive Medi­cine. 2025;(1):63-68
The possibilities of predicting and redu­cing the risk of breast cancer in women against the background of the use of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64
Neoadjuvant drug therapy and onco­logical outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(1):5-12
Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant poly­chemotherapy depe­nding on Ki-67 levels. P.A. Herzen Journal of Onco­logy. 2025;(2):13-18
Abstract:

The development of drugs with the ability to increase differentiation and reduce tumor malignancy is one of the promising directions in the treatment of breast cancer (BC). As such, Human Leukemia Differentiation Factor (HLDF), a protein consisting of 54 amino acids and contributing to an increase in the degree of differentiation of invasive ductal breast carcinoma cells, can be used. The key disadvantage of the full-size HLDF is its rapid biodegradation. In this connection, the acetylamide form of the peptide (HLDF-6) was synthesized to protect against hydrolysis.

OBJECTIVE

To evaluate the effect of HLDF-6 on cell differentiation in various molecular biological subtypes of breast cancer.

MATERIAL AND METHODS

The relative content of tumor cells of various degrees of differentiation in biopsies of 33 women with breast cancer when exposed to HLDF-6 tumor was evaluated.

RESULTS

HLDF-6 significantly increases the relative content of differentiated cells in the luminal B HER2-negative subtype of breast cancer, without significantly affecting the cells of patients with luminal A and basal-like subtypes.

CONCLUSION

The study revealed the prospects of using HLDF-6 as part of differentiating therapy in patients with luminal B HER2-negative subtype of breast cancer.

Keywords:

breast cancer
molecular subtypes
differentiation factor

Authors:

Studenikina A.A.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

Mangazeeva E.D.

Novosibirsk State Medical University

Bogachuk A.P.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry

Lipkin V.M.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry

Autenshlyus A.I.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

Received:

26.06.2024

Accepted:

18.12.2024

Close metadata

References:

  1. Bright EE, Finkelstein LB, Nealis MS, Genung SR, Wrigley J, Gu HCJ, Schmiege SJ, Arch JJ. A systematic review and meta-analysis of interventions to promote adjuvant endocrine therapy adherence among breast cancer survivors. J Clin Oncol. 2023;41(28):4548-4561. https://doi.org/10.1200/JCO.23.00697
  2. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al. NCCN Guidelines® Insights: breast cancer, version 4.2021. J Natl Compr Canc Netw. 2021;19(5):484-493.  https://doi.org/10.6004/jnccn.2021.0023
  3. Fotinós J, Barberis L, Condat CA. Effects of a differentiating therapy on cancer-stem-cell-driven tumors. J Theor Biol. 2023;572:111563. https://doi.org/10.1016/j.jtbi.2023.111563
  4. Yan M, Liu Q. Differentiation therapy: a promising strategy for cancer treatment. Chin J Cancer. 2016;35:3.  https://doi.org/10.1186/s40880-015-0059-x
  5. Bar-Hai N, Ishay-Ronen D. Engaging plasticity: differentiation therapy in solid tumors. Front Pharmacol. 2022;13:944773. https://doi.org/10.3389/fphar.2022.944773
  6. Autenshlyus AA, Zhurakovskii IP, Mikhailova ES, Davletova KI, Bernado AV, Studenkina AA, Proskura AV, Sidorov SV, Marinkin IO, Lyakhovich VV, Bogachuk AP, Lipkin VM. Sredstvo, snizhayushchee otnositel’noe soderzhanie nizkodifferentsirovannykh i povyshayushchee otnositel’noe soderzhanie vysokodifferentsirovannykh kletok v invazivnoi kartsinome molochnoi zhelezy nespetsificheskogo tipa. Patent RF na izobretenie №2743710/24.02.2021. Byulleten’ №6. (In Russ.). Accessed 20.06.2024. https://searchplatform.rospatent.gov.ru/doc/RU2743710C1_20210224?q=&from=search_simple&hash=256003455
  7. Autenshlyus AI, Zhurakovsky IP, Davletova KI, Bogachuk AP, Lyakhovich VV, Lipkin VM. Influence of HLDF differentiation factor on nonspecific invasive breast carcinoma in vitro. Dokl Biochem Biophys. 2020;495(1):289-291.  https://doi.org/10.1134/S1607672920060010
  8. Autenshlyus AA, Zhurakovskii IP, Marinkin IO, Bogachuk AP, Lipkin VM. Sredstvo, snizhayushchee otnositel’noe soderzhanie nizkodifferentsirovannykh i povyshayushchee otnositel’noe soderzhanie vysokodifferentsirovannykh kletok v invazivnoi kartsinome molochnoi zhelezy nespetsificheskogo tipa. Patent RF na izobretenie №2786528/21.12.2022. Byulleten’ №36. Accessed 20.06.2024. https://searchplatform.rospatent.gov.ru/doc/RU2786528C1_20221221?q=&from=search_simple&hash=1258907589
  9. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207.  https://doi.org/10.1186/bcr2607
  10. Tyulyandin SA, Artamonova EV, Zhigulev AN, Koroleva IA, Parokonnaya AA, Semiglazova TYu, Stenina MB, Frolova MA. Breast cancer. Malignant tumors. 2023;13(3s2-1):157-200. (In Russ.). https://doi.org/10.18027/2224-5057-2023-13-3s2-1-157-200
  11. Zhang X. Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med. 2023;147(1):46-51.  https://doi.org/10.5858/arpa.2022-0070-RA
  12. Noske A, Anders SI, Ettl J, Hapfelmeier A, Steiger K, Specht K, Weichert W, Kiechle M, Klein E. Risk stratification in luminal-type breast cancer: comparison of Ki-67 with EndoPredict test results. Breast. 2020;49:101-107.  https://doi.org/10.1016/j.breast.2019.11.004
  13. Jin X, Zhou YF, Ma D, Zhao S, Lin CJ, Xiao Y, Fu T, Liu CL, Chen YY, Xiao WX, et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023; 55(10):1696-1708. https://doi.org/10.1038/s41588-023-01507-7
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.